MEIJI SEIKA PHARMA CO., LTD.

Meiji Seika Pharma invests USD 20 million in MPM BioImpact, a biotech firm, to access new technologies and enhance its global network. This partnership aims to develop transformative therapies for unmet medical needs, focusing on infectious diseases and innovative healthcare solutions.

Meiji Seika Pharma Co., Ltd. invests USD 20 million in MPM BioImpact LLC to access new technologies and virology strategies, aiming to enhance its global network and R&D in infectious diseases. MPM BioImpact, with 30 years of experience, focuses on breakthrough therapies, including next-gen antibodies and gene therapies, to address unmet medical needs.

Meiji Seika Pharma Co., Ltd. established Taiwan Meiji Pharma Co., Ltd. in Taipei, aiming to focus on pharmaceutical sales in Taiwan, starting operations in February 2025. It plans to launch “REZUROCK” for chronic GVHD treatment and introduce other products like antibiotics and vaccines.